Literature DB >> 22072212

Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.

Seyed H Ghaffari1, Davood Bashash, Majid Zaki Dizaji, Ardeshir Ghavamzadeh, Kamran Alimoghaddam.   

Abstract

MicroRNAs (miRNAs) are involved in cancer pathogenesis, apoptosis, and cell growth, and these miRNAs are thought to be functional as oncogenes and/or tumor suppressors in the gene regulatory networks. We studied the potential contribution of miRNAs in acute promyelocytic leukemia (APL) cell NB4 during the apoptosis induction by arsenic trioxide (ATO). The apoptotic effects of ATO on the NB4 cell line at a pharmacological dose (2 μM) was verified using cell growth and viability assays, MTT assay, BrdU cell proliferation assay, flow cytometric analysis, and caspase-3 activity assay. miRNAs from untreated and 2 μM ATO-treated NB4 cell line were extracted, purified, and converted to complementary DNAs. Differential expressions of 88 cancer-related miRNAs were analyzed by real-time reverse transcription PCR using miRNA PCR cancer-array system. After normalizing to the average Ct value of three housekeeping genes in the array (U6, SNORD47, and SNORD48), the fold change of miRNAs was calculated in the ATO-treated cells as compared to untreated. Among the 88 cancer-focused miRNAs, 51 miRNAs were found to be differentially expressed more than 2-fold after ATO treatment. Of these, 48 miRNAs were upregulated up to 21.65-fold changes, while three miRNAs were downregulated up to 5.19-fold changes. By screening the literature, a majority of these upregulated miRNAs were found to have tumor and/or metastatic suppressors' functions associated with cell cycle arrest and apoptosis, as well as inhibition of angiogenesis, invasion, and metastasis. Our results demonstrate that ATO, at the relevant concentration, modulate a substantial number of cancer-related miRNAs in APL cell line; most of these are known to function as a tumor and/or metastatic suppressors and have confirmed targets involved in cell cycle arrest and apoptosis. The results of this study support the hypothesis that miRNAs may play a mediatory role in eliciting the multi-target and pleiotropic action of ATO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072212     DOI: 10.1007/s13277-011-0259-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  71 in total

Review 1.  Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.

Authors:  Dennis A Carney
Journal:  Leuk Lymphoma       Date:  2008-10

2.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

3.  Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3.

Authors:  X H Jiang; B C Wong; S T Yuen; S H Jiang; C H Cho; K C Lai; M C Lin; H F Kung; S K Lam; B Chun-Yu Wong
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

4.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

Review 5.  MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.

Authors:  Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Clara D Bloomfield; Carlo M Croce
Journal:  Best Pract Res Clin Haematol       Date:  2009-06       Impact factor: 3.020

Review 6.  MiRNAs and cancer.

Authors:  Rosa Visone; Carlo M Croce
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

7.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

8.  Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Akio Iio; Tomoki Naoe
Journal:  Leuk Res       Date:  2009-05-21       Impact factor: 3.156

9.  Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells.

Authors:  Lili Jiang; Qin Huang; Siyang Zhang; Qingfu Zhang; Jihong Chang; Xueshan Qiu; Enhua Wang
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

10.  Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia.

Authors:  Amanda Dixon-McIver; Phil East; Charles A Mein; Jean-Baptiste Cazier; Gael Molloy; Tracy Chaplin; T Andrew Lister; Bryan D Young; Silvana Debernardi
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

View more
  16 in total

Review 1.  State of the science review of the health effects of inorganic arsenic: Perspectives for future research.

Authors:  Paul B Tchounwou; Clement G Yedjou; Udensi K Udensi; Maricica Pacurari; Jacqueline J Stevens; Anita K Patlolla; Felicite Noubissi; Sanjay Kumar
Journal:  Environ Toxicol       Date:  2018-12-04       Impact factor: 4.119

2.  The Potential Contribution of microRNAs in Anti-cancer Effects of Aurora Kinase Inhibitor (AZD1152-HQPA).

Authors:  Ali Zekri; Yashar Mesbahi; Elham Boustanipour; Zahra Sadr; Seyed H Ghaffari
Journal:  J Mol Neurosci       Date:  2018-07-26       Impact factor: 3.444

Review 3.  Analysis of the transcriptome in molecular epidemiology studies.

Authors:  Cliona M McHale; Luoping Zhang; Reuben Thomas; Martyn T Smith
Journal:  Environ Mol Mutagen       Date:  2013-08-01       Impact factor: 3.216

4.  Prenatal arsenic exposure and the epigenome: altered microRNAs associated with innate and adaptive immune signaling in newborn cord blood.

Authors:  Julia E Rager; Kathryn A Bailey; Lisa Smeester; Sloane K Miller; Joel S Parker; Jessica E Laine; Zuzana Drobná; Jenna Currier; Christelle Douillet; Andrew F Olshan; Marisela Rubio-Andrade; Miroslav Stýblo; Gonzalo García-Vargas; Rebecca C Fry
Journal:  Environ Mol Mutagen       Date:  2013-12-10       Impact factor: 3.216

5.  Prediction of disease-related interactions between microRNAs and environmental factors based on a semi-supervised classifier.

Authors:  Xing Chen; Ming-Xi Liu; Qing-Hua Cui; Gui-Ying Yan
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 6.  Arsenic-Associated Changes to the Epigenome: What Are the Functional Consequences?

Authors:  Kathryn A Bailey; Rebecca C Fry
Journal:  Curr Environ Health Rep       Date:  2014-01-19

7.  Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.

Authors:  Yuhua Fan; Meng Chen; Jia Meng; Lei Yu; Yingfeng Tu; Lin Wan; Kun Fang; Wenliang Zhu
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

8.  Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia.

Authors:  Fei-Fei Wang; Ming-Zhu Liu; Yi Sui; Qing Cao; Bo Yan; Mei-Ling Jin; Xi Mo
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

Review 9.  From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia.

Authors:  Naeim Ehtesham; Mohammadreza Sharifi
Journal:  Adv Biomed Res       Date:  2016-11-28

Review 10.  Arsenic Exposure and Type 2 Diabetes: MicroRNAs as Mechanistic Links?

Authors:  Rowan Beck; Miroslav Styblo; Praveen Sethupathy
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.